Home/Pipeline/Microlyte® SAM™ Commercial Launch

Microlyte® SAM™ Commercial Launch

Chronic Wounds (e.g., Diabetic Foot Ulcers, Venous Leg Ulcers)

CommercialActive

Key Facts

Indication
Chronic Wounds (e.g., Diabetic Foot Ulcers, Venous Leg Ulcers)
Phase
Commercial
Status
Active
Company

About BioLab Holdings

BioLab Holdings, founded in 2018 and headquartered in Miami, is a private commercial-stage company in the tissue engineering and regenerative medicine sector. It has a portfolio of marketed wound care products, including amniotic membrane allografts and a synthetic antimicrobial matrix, targeting the chronic wound market. The company emphasizes a patient-first philosophy, partners with distributors and providers, and is experiencing team growth to support its commercial and R&D activities.

View full company profile

Therapeutic Areas

Other Chronic Wounds (e.g., Diabetic Foot Ulcers, Venous Leg Ulcers) Drugs

DrugCompanyPhase
OCM™OmezaApproved